Dupont Capital Management Corp Intellia Therapeutics, Inc. Transaction History

Dupont Capital Management Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 27, 2022	SELL	$58.27 - $118.99 $11,537 - $23,560	-198 Reduced 8.16%	2,228 $162,000
Q4 2021 Jan 31, 2022	SELL	$100.76 - $138.36 $97,535 - $133,932	-968 Reduced 28.52%	2,426 $287,000
Q3 2021 Nov 03, 2021	SELL	$132.37 - $176.78 $783,498 - $1.05 Million	-5,919 Reduced 63.56%	3,394 $455,000
Q2 2021 Jul 30, 2021	SELL	$60.88 - $161.91 $265,254 - $705,441	-4,357 Reduced 31.87%	9,313 $1.51 Million
Q1 2021 Apr 29, 2021	SELL	$46.59 - $83.68 $559,592 - $1.01 Million	-12,011 Reduced 46.77%	13,670 $1.1 Million
Q4 2020 Jan 28, 2021	SELL	$18.83 - $63.53 $36,097 - $121,787	-1,917 Reduced 6.95%	25,681 $1.4 Million
Q3 2020 Oct 29, 2020	SELL	$17.47 - $24.93 $32,302 - $46,095	-1,849 Reduced 6.28%	27,598 $549,000
Q2 2020 Jul 24, 2020	SELL	$11.14 - $22.87 $29,287 - $60,125	-2,629 Reduced 8.2%	29,447 $619,000
Q4 2019 Jan 27, 2020	BUY	$10.43 - $17.67 $83,961 - $142,243	8,050 Added 33.51%	32,076 $471,000
Q3 2019 Oct 28, 2019	BUY	$13.07 - $18.51 $314,019 - $444,721	24,026 New	24,026 $321,000

336

96.1M

1.06M

863K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $707M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.